Vikbladh, Teodor
Troberg, Katja
Håkansson, Anders
Dahlman, Disa
Funding for this research was provided by:
Southern Health Care Region
Region Skåne (Psychiatry and habilitation internal grants, Research funding granted from the Primary Healthcare Management)
Lunds Universitet (ALF project grant, ALF research grant "Yngre ALF")
Lund University
Article History
Received: 14 February 2022
Accepted: 20 July 2022
First Online: 29 July 2022
Declarations
:
: The study was conducted in accordance with the Declaration of Helsinki 2013 and was approved by the Regional Ethics Board, Lund (file nr 2016/1105). Prior to patient inclusion, oral and written information about the study was given to all patients prior to retrieving informed consent. No economic compensation was provided for study participation.
: Not applicable.
: AH holds a position at Lund University sponsored by the Swedish state-owned gambling operator AB Svenska Spel. He disposes research grants from the research councils of AB Svenska Spel and the state-owned alcohol monopoly Systembolaget AB. He is involved in a clinical research study which receives non-financial support from the commercial body Kontigo Care in digital follow-up tools in the treatment of addictive disorders. He has been the national principal investigator of a prior pharmaco-epidemiological survey study conducted by the US research institute Research Triangle Institute and which was sponsored by a pharmaceutical company (Shire), which supported the study but did not pay any personal fees to AH as an individual researcher. None of these organizations are involved in any aspect of the present project.Authors TV, KT and DD declare that they have no conflicts of interest related to this study.